{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:22:38Z","timestamp":1789129358430,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-65681-4","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:02:25Z","timestamp":1765879345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-8015","authenticated-orcid":false,"given":"Mark W.","family":"Youngblood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-3699","authenticated-orcid":false,"given":"Abha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Tae","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Habashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5992-957X","authenticated-orcid":false,"given":"Harika","family":"Lingamarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Morey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrshavasan","family":"Congivaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-5649","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3834-2439","authenticated-orcid":false,"given":"Thomas K.","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-830X","authenticated-orcid":false,"given":"Kathleen","family":"McCortney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna C.","family":"Pituch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Torres Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Zarrieneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Vandermolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimas V.","family":"Lukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1688-9663","authenticated-orcid":false,"given":"Crismita","family":"Dmello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouchoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Canney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Amidei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5483-3118","authenticated-orcid":false,"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1497-7977","authenticated-orcid":false,"given":"Sunitha","family":"Nagrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-1945","authenticated-orcid":false,"given":"Adam M.","family":"Sonabend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"65681_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"65681_CR2","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","volume":"26","author":"AA Brandes","year":"2008","unstructured":"Brandes, A. A. et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26, 2192\u20132197 (2008).","journal-title":"J. Clin. Oncol."},{"key":"65681_CR3","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2005.04.5963","volume":"24","author":"RO Mirimanoff","year":"2006","unstructured":"Mirimanoff, R. O. et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981\/22981-NCIC CE3 phase III randomized trial. J. Clin. Oncol. 24, 2563\u20132569 (2006).","journal-title":"J. Clin. Oncol."},{"key":"65681_CR4","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"65681_CR5","first-page":"1967","volume":"26","author":"ME Mullins","year":"2005","unstructured":"Mullins, M. E. et al. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am. J. Neuroradiol. 26, 1967\u20131972 (2005).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"65681_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-007-9341-3","volume":"84","author":"QS Zeng","year":"2007","unstructured":"Zeng, Q. S. et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J. Neurooncol. 84, 63\u201369 (2007).","journal-title":"J. Neurooncol."},{"key":"65681_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cancers14020288","volume":"14","author":"H Abouali","year":"2022","unstructured":"Abouali, H., Hosseini, S. A., Purcell, E., Nagrath, S. & Poudineh, M. Recent advances in device engineering and computational analysis for characterization of cell-released cancer biomarkers. Cancers (Basel) 14, 288 (2022).","journal-title":"Cancers (Basel)"},{"key":"65681_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel, G., D\u2019Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213\u2013228 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"65681_CR9","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1039\/D2LC00232A","volume":"22","author":"NE Onukwugha","year":"2022","unstructured":"Onukwugha, N. E., Kang, Y. T. & Nagrath, S. Emerging micro-nanotechnologies for extracellular vesicles in immuno-oncology: from target specific isolations to immunomodulation. Lab Chip 22, 3314\u20133339 (2022).","journal-title":"Lab Chip"},{"key":"65681_CR10","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.2147\/IJN.S272378","volume":"15","author":"VC Kok","year":"2020","unstructured":"Kok, V. C. & Yu, C. C. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int. J. Nanomed. 15, 8019\u20138036 (2020).","journal-title":"Int. J. Nanomed."},{"key":"65681_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","volume":"182","author":"A Hoshino","year":"2020","unstructured":"Hoshino, A. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 182, 1044\u20131061.e18 (2020).","journal-title":"Cell"},{"key":"65681_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","volume":"24","author":"AM Sonabend","year":"2023","unstructured":"Sonabend, A. M. et al. Repeated blood\u2013brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24, 509\u2013522 (2023).","journal-title":"Lancet Oncol."},{"key":"65681_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45818-7","volume":"15","author":"A Carpentier","year":"2024","unstructured":"Carpentier, A. et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial. Nat. Commun. 15, 1650 (2024).","journal-title":"Nat. Commun."},{"key":"65681_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48326-w","volume":"15","author":"VA Arrieta","year":"2024","unstructured":"Arrieta, V. A. et al. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat. Commun. 15, 4698 (2024).","journal-title":"Nat. Commun."},{"key":"65681_CR15","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1158\/1078-0432.CCR-23-2367","volume":"30","author":"KJ Habashy","year":"2024","unstructured":"Habashy, K. J. et al. Paclitaxel and carboplatin in combination with low-intensity pulsed ultrasound for glioblastoma. Clin. Cancer Res. 30, 1619\u20131629 (2024).","journal-title":"Clin. Cancer Res."},{"key":"65681_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1158\/1078-0432.CCR-19-2182","volume":"26","author":"DY Zhang","year":"2020","unstructured":"Zhang, D. Y. et al. Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations. Clin. Cancer Res. 26, 477\u2013486 (2020).","journal-title":"Clin. Cancer Res."},{"key":"65681_CR17","doi-asserted-by":"crossref","unstructured":"Habashy, K. J. et al. Pharmacokinetic analysis of carboplatin and fluorescein brain retention following ultrasound-based blood-brain barrier opening. Clin. Cancer Res. 31, 3562\u20133570 (2025).","DOI":"10.1158\/1078-0432.CCR-25-0080"},{"key":"65681_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001581","volume":"7","author":"YT Kang","year":"2020","unstructured":"Kang, Y. T. et al. Dual-isolation and profiling of circulating tumor cells and cancer exosomes from blood samples with melanoma using immunoaffinity-based microfluidic interfaces. Adv. Sci. 7, 2001581 (2020).","journal-title":"Adv. Sci."},{"key":"65681_CR19","doi-asserted-by":"publisher","first-page":"112535","DOI":"10.1016\/j.bios.2020.112535","volume":"168","author":"YT Kang","year":"2020","unstructured":"Kang, Y. T., Hadlock, T., Jolly, S. & Nagrath, S. Extracellular vesicles on demand (EVOD) chip for screening and quantification of cancer-associated extracellular vesicles. Biosens. Bioelectron. 168, 112535 (2020).","journal-title":"Biosens. Bioelectron."},{"key":"65681_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003747","volume":"8","author":"YT Kang","year":"2021","unstructured":"Kang, Y. T. et al. On-chip biogenesis of circulating NK cell-derived exosomes in non-small cell lung cancer exhibits antitumoral activity. Adv. Sci. 8, 2003747 (2021).","journal-title":"Adv. Sci."},{"key":"65681_CR21","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1039\/C9AN01235D","volume":"144","author":"YT Kang","year":"2019","unstructured":"Kang, Y. T. et al. Multiplex isolation and profiling of extracellular vesicles using a microfluidic DICE device. Analyst 144, 5785\u20135793 (2019).","journal-title":"Analyst"},{"key":"65681_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12340","volume":"12","author":"B Kim","year":"2023","unstructured":"Kim, B. et al. Palmitate and glucose increase amyloid precursor protein in extracellular vesicles: missing link between metabolic syndrome and Alzheimer\u2019s disease. J. Extracell. Vesicles 12, e12340 (2023).","journal-title":"J. Extracell. Vesicles"},{"key":"65681_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","volume":"32","author":"EM Hol","year":"2015","unstructured":"Hol, E. M. & Pekny, M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr. Opin. Cell Biol. 32, 121\u2013130 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"65681_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22126-y","volume":"12","author":"E Bonsergent","year":"2021","unstructured":"Bonsergent, E. et al. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. Nat. Commun. 12, 1864 (2021).","journal-title":"Nat. Commun."},{"key":"65681_CR25","doi-asserted-by":"publisher","first-page":"E968","DOI":"10.1073\/pnas.1521230113","volume":"113","author":"J Kowal","year":"2016","unstructured":"Kowal, J. et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Natl. Acad. Sci. USA 113, E968\u2013E977 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65681_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/membranes4030356","volume":"4","author":"M Meister","year":"2014","unstructured":"Meister, M. & Tikkanen, R. Endocytic trafficking of membrane-bound cargo: a flotillin point of view. Membranes 4, 356\u2013371 (2014).","journal-title":"Membranes"},{"key":"65681_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature07961","volume":"458","author":"C Raiborg","year":"2009","unstructured":"Raiborg, C. & Stenmark, H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445\u2013452 (2009).","journal-title":"Nature"},{"key":"65681_CR28","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nsb1195-968","volume":"2","author":"MA Swairjo","year":"1995","unstructured":"Swairjo, M. A., Concha, N. O., Kaetzel, M. A., Dedman, J. R. & Seaton, B. A. Ca(2+)-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V. Nat. Struct. Biol. 2, 968\u2013974 (1995).","journal-title":"Nat. Struct. Biol."},{"key":"65681_CR29","doi-asserted-by":"publisher","first-page":"30678","DOI":"10.18632\/oncotarget.8929","volume":"7","author":"TJ Desai","year":"2016","unstructured":"Desai, T. J., Toombs, J. E., Minna, J. D., Brekken, R. A. & Udugamasooriya, D. G. Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. Oncotarget 7, 30678\u201330690 (2016).","journal-title":"Oncotarget"},{"key":"65681_CR30","doi-asserted-by":"publisher","first-page":"14395","DOI":"10.18632\/oncotarget.14795","volume":"8","author":"J Lea","year":"2017","unstructured":"Lea, J. et al. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study. Oncotarget 8, 14395\u201314407 (2017).","journal-title":"Oncotarget"},{"key":"65681_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201903600","volume":"15","author":"YT Kang","year":"2019","unstructured":"Kang, Y. T. et al. Isolation and profiling of circulating tumor-associated exosomes using extracellular vesicular lipid-protein binding affinity based microfluidic device. Small 15, e1903600 (2019).","journal-title":"Small"},{"key":"65681_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1579541","volume":"8","author":"S Matsumura","year":"2019","unstructured":"Matsumura, S. et al. Subtypes of tumour cell-derived small extracellular vesicles having differently externalized phosphatidylserine. J. Extracell. Vesicles 8, 1579541 (2019).","journal-title":"J. Extracell. Vesicles"},{"key":"65681_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5301\/ijbm.5000301","volume":"33","author":"FS Saadeh","year":"2018","unstructured":"Saadeh, F. S., Mahfouz, R. & Assi, H. I. EGFR as a clinical marker in glioblastomas and other gliomas. Int. J. Biol. Markers 33, 22\u201332 (2018).","journal-title":"Int. J. Biol. Markers"},{"key":"65681_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/MPA.0000000000000847","volume":"46","author":"M Khushman","year":"2017","unstructured":"Khushman, M. et al. Exosomal markers (CD63 and CD9) expression pattern using immunohistochemistry in resected malignant and nonmalignant pancreatic specimens. Pancreas 46, 782\u2013788 (2017).","journal-title":"Pancreas"},{"key":"65681_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep22519","volume":"6","author":"E Willms","year":"2016","unstructured":"Willms, E. et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci. Rep. 6, 22519 (2016).","journal-title":"Sci. Rep."},{"key":"65681_CR36","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/iid3.515","volume":"9","author":"Q Yuan","year":"2021","unstructured":"Yuan, Q. et al. Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma. Immun. Inflamm. Dis. 9, 1618\u20131630 (2021).","journal-title":"Immun. Inflamm. Dis."},{"key":"65681_CR37","doi-asserted-by":"publisher","first-page":"21812","DOI":"10.18632\/aging.203603","volume":"13","author":"ES Norton","year":"2021","unstructured":"Norton, E. S., Da Mesquita, S. & Guerrero-Cazares, H. SERPINA3 in glioblastoma and Alzheimer\u2019s disease. Aging (Albany NY) 13, 21812\u201321813 (2021).","journal-title":"Aging (Albany NY)"},{"key":"65681_CR38","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2147\/OTT.S133022","volume":"10","author":"D Luo","year":"2017","unstructured":"Luo, D. et al. Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is overexpressed in glioma and associated with poor prognosis in glioma patients. Onco Targets Ther. 10, 2173\u20132181 (2017).","journal-title":"Onco Targets Ther."},{"key":"65681_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21216-1","volume":"12","author":"M Hilbert","year":"2022","unstructured":"Hilbert, M., Kuzman, P., Mueller, W. C., Meixensberger, J. & Nestler, U. Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study. Sci. Rep. 12, 16981 (2022).","journal-title":"Sci. Rep."},{"key":"65681_CR40","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41401-022-00917-3","volume":"43","author":"XJ Zheng","year":"2022","unstructured":"Zheng, X. J. et al. Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1\/NRF2 and CBS-regulated ferroptosis. Acta Pharm. Sin. 43, 2977\u20132992 (2022).","journal-title":"Acta Pharm. Sin."},{"key":"65681_CR41","doi-asserted-by":"crossref","unstructured":"Ruiz-Moreno, C. et al. Charting the single-cell and spatial landscape of IDH-wild-type glioblastoma with GBmap. Neuro Oncol. 27, 2281\u20132295 (2025).","DOI":"10.1093\/neuonc\/noaf113"},{"key":"65681_CR42","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","volume":"8","author":"JZ Bakdash","year":"2017","unstructured":"Bakdash, J. Z. & Marusich, L. R. Repeated measures correlation. Front. Psychol. 8, 456 (2017).","journal-title":"Front. Psychol."},{"key":"65681_CR43","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1158\/1078-0432.CCR-21-2563","volume":"28","author":"C Dmello","year":"2022","unstructured":"Dmello, C. et al. Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma. Clin. Cancer Res. 28, 3156\u20133169 (2022).","journal-title":"Clin. Cancer Res."},{"key":"65681_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41416-021-01594-5","volume":"126","author":"R Mair","year":"2022","unstructured":"Mair, R. & Mouliere, F. Cell-free DNA technologies for the analysis of brain cancer. Br. J. Cancer 126, 371\u2013378 (2022).","journal-title":"Br. J. Cancer"},{"key":"65681_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-019-0603-6","volume":"122","author":"J M\u00fcller Bark","year":"2020","unstructured":"M\u00fcller Bark, J., Kulasinghe, A., Chua, B., Day, B. W. & Punyadeera, C. Circulating biomarkers in patients with glioblastoma. Br. J. Cancer 122, 295\u2013305 (2020).","journal-title":"Br. J. Cancer"},{"key":"65681_CR46","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.gendis.2022.03.021","volume":"10","author":"M Xu","year":"2023","unstructured":"Xu, M. et al. The biogenesis and secretion of exosomes and multivesicular bodies (MVBs): intercellular shuttles and implications in human diseases. Genes Dis. 10, 1894\u20131907 (2023).","journal-title":"Genes Dis."},{"key":"65681_CR47","doi-asserted-by":"publisher","first-page":"461773","DOI":"10.1016\/j.chroma.2020.461773","volume":"1636","author":"T Liangsupree","year":"2021","unstructured":"Liangsupree, T., Multia, E. & Riekkola, M. L. Modern isolation and separation techniques for extracellular vesicles. J. Chromatogr. A 1636, 461773 (2021).","journal-title":"J. Chromatogr. A"},{"key":"65681_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02261-1","volume":"9","author":"E Re\u00e1tegui","year":"2018","unstructured":"Re\u00e1tegui, E. et al. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat. Commun. 9, 175 (2018).","journal-title":"Nat. Commun."},{"key":"65681_CR49","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/nm.2994","volume":"18","author":"H Shao","year":"2012","unstructured":"Shao, H. et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18, 1835\u20131840 (2012).","journal-title":"Nat. Med."},{"key":"65681_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7999","volume":"6","author":"H Shao","year":"2015","unstructured":"Shao, H. et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat. Commun. 6, 6999 (2015).","journal-title":"Nat. Commun."},{"key":"65681_CR51","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1039\/B916199F","volume":"10","author":"C Chen","year":"2010","unstructured":"Chen, C. et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 10, 505\u2013511 (2010).","journal-title":"Lab Chip"},{"key":"65681_CR52","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/sj.cdd.4400908","volume":"8","author":"M Maccarrone","year":"2001","unstructured":"Maccarrone, M., Melino, G. & Finazzi-Agr\u00f2, A. Lipoxygenases and their involvement in programmed cell death. Cell Death Differ. 8, 776\u2013784 (2001).","journal-title":"Cell Death Differ."},{"key":"65681_CR53","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.2174\/138161209788923903","volume":"15","author":"H Kenis","year":"2009","unstructured":"Kenis, H. & Reutelingsperger, C. Targeting phosphatidylserine in anti-cancer therapy. Curr. Pharm. Des. 15, 2719\u20132723 (2009).","journal-title":"Curr. Pharm. Des."},{"key":"65681_CR54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","volume":"11","author":"JG Nicholson","year":"2021","unstructured":"Nicholson, J. G. & Fine, H. A. Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov. 11, 575\u2013590 (2021).","journal-title":"Cancer Discov."},{"key":"65681_CR55","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","volume":"28","author":"MA Qazi","year":"2017","unstructured":"Qazi, M. A. et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann. Oncol. 28, 1448\u20131456 (2017).","journal-title":"Ann. Oncol."},{"key":"65681_CR56","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","volume":"2","author":"VA Arrieta","year":"2021","unstructured":"Arrieta, V. A. et al. ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat. Cancer 2, 1372\u20131386 (2021).","journal-title":"Nat. Cancer"},{"key":"65681_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"65681_CR58","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S1470-2045(20)30328-4","volume":"21","author":"S Billan","year":"2020","unstructured":"Billan, S., Kaidar-Person, O. & Gil, Z. Treatment after progression in the era of immunotherapy. Lancet Oncol. 21, e463\u2013e476 (2020).","journal-title":"Lancet Oncol."},{"key":"65681_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790674","volume":"12","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma. Front. Immunol. 12, 790674 (2021).","journal-title":"Front. Immunol."},{"key":"65681_CR60","first-page":"4043","volume":"6","author":"SM Poelman","year":"2000","unstructured":"Poelman, S. M. et al. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin. Cancer Res. 6, 4043\u20134048 (2000).","journal-title":"Clin. Cancer Res."},{"key":"65681_CR61","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/sj.bjc.6603182","volume":"94","author":"K Mimori","year":"2006","unstructured":"Mimori, K. et al. Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Br. J. Cancer 94, 1894\u20131897 (2006).","journal-title":"Br. J. Cancer"},{"key":"65681_CR62","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/jcb.23134","volume":"112","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. J. Cell Biochem. 112, 2125\u20132137 (2011).","journal-title":"J. Cell Biochem."},{"key":"65681_CR63","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3171\/2016.11.JNS161187","volume":"128","author":"SV Manda","year":"2018","unstructured":"Manda, S. V. et al. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. J. Neurosurg. 128, 1091\u20131101 (2018).","journal-title":"J. Neurosurg."},{"key":"65681_CR64","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","volume":"10","author":"J Skog","year":"2008","unstructured":"Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470\u20131476 (2008).","journal-title":"Nat. Cell Biol."},{"key":"65681_CR65","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/neuonc\/nox085","volume":"19","author":"JM Figueroa","year":"2017","unstructured":"Figueroa, J. M. et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 19, 1494\u20131502 (2017).","journal-title":"Neuro Oncol."},{"key":"65681_CR66","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1096\/fj.08-122184","volume":"23","author":"MW Graner","year":"2009","unstructured":"Graner, M. W. et al. Proteomic and immunologic analyses of brain tumor exosomes. Faseb J. 23, 1541\u20131557 (2009).","journal-title":"Faseb J."},{"key":"65681_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1180","volume":"2","author":"L Balaj","year":"2011","unstructured":"Balaj, L. et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011).","journal-title":"Nat. Commun."},{"key":"65681_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-22","volume":"12","author":"M Noerholm","year":"2012","unstructured":"Noerholm, M. et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 12, 22 (2012).","journal-title":"BMC Cancer"},{"key":"65681_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813747","volume":"12","author":"J Peng","year":"2021","unstructured":"Peng, J. et al. Current understanding of exosomal microRNAs in glioma immune regulation and therapeutic responses. Front. Immunol. 12, 813747 (2021).","journal-title":"Front. Immunol."},{"key":"65681_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51332-7","volume":"15","author":"SM Batool","year":"2024","unstructured":"Batool, S. M. et al. Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas. Nat. Commun. 15, 7074 (2024).","journal-title":"Nat. Commun."},{"key":"65681_CR71","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1158\/1078-0432.CCR-18-1941","volume":"25","author":"D Osti","year":"2019","unstructured":"Osti, D. et al. Clinical significance of extracellular vesicles in plasma from glioblastoma patients. Clin. Cancer Res. 25, 266\u2013276 (2019).","journal-title":"Clin. Cancer Res."},{"key":"65681_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9839","volume":"6","author":"L De Mattos-Arruda","year":"2015","unstructured":"De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).","journal-title":"Nat. Commun."},{"key":"65681_CR73","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","volume":"565","author":"AM Miller","year":"2019","unstructured":"Miller, A. M. et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature 565, 654\u2013658 (2019).","journal-title":"Nature"},{"key":"65681_CR74","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-18-3643","volume":"25","author":"A Idbaih","year":"2019","unstructured":"Idbaih, A. et al. Safety and feasibility of repeated and transient blood\u2013brain barrier disruption by pulsed ultrasound in patients with recurrent glioblastoma. Clin. Cancer Res. 25, 3793\u20133801 (2019).","journal-title":"Clin. Cancer Res."},{"key":"65681_CR75","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/neuonc\/noab057","volume":"23","author":"Y Meng","year":"2021","unstructured":"Meng, Y. et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 23, 1789\u20131797 (2021).","journal-title":"Neuro Oncol."},{"key":"65681_CR76","volume":"3","author":"DY Zhang","year":"2021","unstructured":"Zhang, D. Y. et al. Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner. Neurooncol. Adv. 3, vdab165 (2021).","journal-title":"Neurooncol. Adv."},{"key":"65681_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95232-2","volume":"15","author":"GH Tamarindo","year":"2025","unstructured":"Tamarindo, G. H. et al. Distinct proteomic profiles of plasma-derived extracellular vesicles in healthy, benign, and triple-negative breast cancer: candidate biomarkers for liquid biopsy. Sci. Rep. 15, 12122 (2025).","journal-title":"Sci. Rep."},{"key":"65681_CR78","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.14336\/AD.2020.0908","volume":"12","author":"S Muraoka","year":"2021","unstructured":"Muraoka, S. et al. Proteomic profiling of extracellular vesicles separated from plasma of former National Football League players at risk for chronic traumatic encephalopathy. Aging Dis. 12, 1363\u20131375 (2021).","journal-title":"Aging Dis."},{"key":"65681_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-024-00243-4","volume":"26","author":"A Torres","year":"2024","unstructured":"Torres, A. et al. Comparing the proteomic profiles of extracellular vesicles isolated using different methods from long-term stored plasma samples. Biol. Proced. Online 26, 18 (2024).","journal-title":"Biol. Proced. Online"},{"key":"65681_CR80","doi-asserted-by":"publisher","first-page":"10649","DOI":"10.1021\/acsomega.9b00966","volume":"4","author":"IK Sundar","year":"2019","unstructured":"Sundar, I. K., Li, D. & Rahman, I. Proteomic analysis of plasma-derived extracellular vesicles in smokers and patients with chronic obstructive pulmonary disease. ACS Omega 4, 10649\u201310661 (2019).","journal-title":"ACS Omega"},{"key":"65681_CR81","doi-asserted-by":"crossref","unstructured":"Su, H. et al. Multiomics analysis to evaluate the enrichment of extracellular vesicles from human plasma. J. Lipid. Res. 66, 100877 (2025).","DOI":"10.1016\/j.jlr.2025.100877"},{"key":"65681_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12128","volume":"10","author":"RE Veerman","year":"2021","unstructured":"Veerman, R. E. et al. Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin. J. Extracell. Vesicles 10, e12128 (2021).","journal-title":"J. Extracell. Vesicles"},{"key":"65681_CR83","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1021\/acs.jproteome.5c00149","volume":"24","author":"PS Suresh","year":"2025","unstructured":"Suresh, P. S. & Zhang, Q. Comprehensive comparison of methods for isolation of extracellular vesicles from human plasma. J. Proteome Res. 24, 2956\u20132967 (2025).","journal-title":"J. Proteome Res."},{"key":"65681_CR84","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1039\/C4LC00136B","volume":"14","author":"SS Kanwar","year":"2014","unstructured":"Kanwar, S. S., Dunlay, C. J., Simeone, D. M. & Nagrath, S. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip 14, 1891\u20131900 (2014).","journal-title":"Lab Chip"},{"key":"65681_CR85","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1021\/ac502040v","volume":"86","author":"GC McAlister","year":"2014","unstructured":"McAlister, G. C. et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150\u20137158 (2014).","journal-title":"Anal. Chem."},{"key":"65681_CR86","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang, D. et al. SRplot: a free online platform for data visualization and graphing. PLoS ONE 18, e0294236 (2023).","journal-title":"PLoS ONE"},{"key":"65681_CR87","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013d553 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65681-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65681-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:02:28Z","timestamp":1765879348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65681-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65681"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65681-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.S.\u00a0is a paid consultant for Carthera and EnClear Therapies. A.M.S. and R.S\u00a0have received funding support from Carthera and Agenus Bio, and\u00a0in-kind support by Agenus, Carthera, and BMS. R.S.\u00a0serves as a member of the scientific advisory board of Alpheus Medical, Carthera, and has provided consultancy to AstraZeneca, Boston Scientific, Novartis and Novocure. RS has equity in Alpheus Medical and Carthera. M.C. and G.B.\u00a0are full-time employees of Carthera. M.C. has patents and equity interests in Carthera related to this technology. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11045"}}